ReviewCurrent oncology reports2018
Updates on Gallbladder Cancer Management.
Review in Current oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- STMN1 expression is associated with chemotherapy and immunotherapy efficacy in biliary tract cancer.Frontiers in oncology · 2026Article
- Recent Trends in Surgical Strategies of Early-Stage Gallbladder Cancer: A Narrative Review.Journal of clinical medicine · 2025Review
- Article
- Incidental gall bladder cancer in the laparoscopic treatment and magnetic resonance imaging era: A single institution experience.Journal of minimal access surgery · 2024Article
- Identification of Long Noncoding RNAs Expression Profiles Between Gallstone and Gallbladder Cancer Using Next-Generation Sequencing Analysis.International journal of general medicine · 2024Article
- The State of Systematic Therapies in Clinic for Hepatobiliary Cancers.Journal of hepatocellular carcinoma · 2024Review
- DLGAP5 promotes gallbladder cancer migration and tumor-associated macrophage M2 polarization by activating cAMP.Cancer immunology, immunotherapy : CII · 2023Article
- Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.Oncoimmunology · 2023Article
- Successful multimodality treatment of metastatic gallbladder cancer: A case report and review of literature.World journal of clinical cases · 2022Article
- OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis.Translational oncology · 2022Article
- MiR-552-3p promotes malignant progression of gallbladder carcinoma by reactivating the Akt/β-catenin signaling pathway due to inhibition of the tumor suppressor geneAnnals of translational medicine · 2021Article
- The microRNA cluster miR-30b/-30d prevents tumor cell switch from an epithelial to a mesenchymal-like phenotype in GBC.Molecular therapy. Methods & clinical development · 2021Article
- Surgical treatment of gallbladder cancer: An eight-year experience in a single center.World journal of hepatology · 2020Article
- The Landmark Series: Gallbladder Cancer.Annals of surgical oncology · 2020Review
- Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells.Journal of gastrointestinal cancer · 2020Article
- Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions.Clinical and translational gastroenterology · 2019Article
- Calcified gallbladder cancer: is it preventable?Journal of surgical case reports · 2019Article
- Prognostic Significance of Tumour Budding and Tumour-infiltrating Lymphocytes in Gallbladder Carcinoma.Journal of the West African College of SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe will review the current standard of care management for metastatic gallbladder cancer (GBC), recommendations for resection of incidentally or non-incidentally diagnosed GBC, and developments in preoperative risk stratification and adjuvant chemotherapy. RECENT
findingsGemcitabine-cisplatin is the standard of care therapy for advanced-stage disease. Patients with incidentally diagnosed GBC should undergo re-resection for T1b, T2, or T3 disease. The presence of residual disease is associated with decreased survival. Diagnostic laparoscopy should be used in select patients to avoid unnecessary laparotomy. Major hepatectomy and common bile duct excision should only be performed in select cases. Current standard of care for adjuvant therapy includes 6 months of oral capecitabine. Gallbladder cancer continues to carry high mortality rates due to its aggressive course and early spread. Recent developments in preoperative risk stratification, surgical resection, and chemotherapy have greatly shaped management of this malignancy in the current era.
Indexed as
Identifiers
29500514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.